Prostate Cancer and Diseases of the Prostate - Center for Prostate Disease Research

> Integrating basic science and clinical research to develop promising detection techniques and treatments for prostate disease

The CPDR mission is fulfilled primarily through its three principal programs – the Clinical Research Program, the Basic Science Research Program and the Multicenter National Prostate Cancer Database – and through a robust education and training program that operates out of its Headquarters location, the Clinical Research Center, and the original laboratories at USUHS. CPDR is also committed to patient outreach, primarily through its affiliation with the WRAMC US TOO! organization and through a heavy schedule of health fairs in which it participates.

To get started, find your selected interest below or use the blue navigation bar above.

CLINICIAN RESEARCHER PATIENT CPDR STAFF LISTING BY PROGRAM CPDR PARADIGM

> NEWS

Dr. Sterbis Receives BKA Award

Thursday, June 19, 2008

The Department of Clinical Investigation at Walter Reed Army Medical Center recently held the 34th annual Bailey K. Ashford Clinical and Laboratory Research Award and Symposium on My 1st 2008. The BKA award is presented annually to the graduating trainee who has contributed the most significant research to the clinical investigation program during their years of training at WRAMC. Nominees must have made a prime contribution to the intellectual and organizational development of the research, and the research must have been received the right institutional review.

Full Article

Agent Orange, Vietnam Veterans and Prostate Cancer

Monday, June 16, 2008

2008 UPDATE Vietnam veterans diagnosed with prostate cancer may qualify for service-connected disability compensation. Veterans who served in Korea in 1968 or 1969 may also qualify.

read more ...

AUA 2008 Highlights

Thursday, June 10, 2008

The 103rd annual American Urological Association (AUA) meeting was held in Orange County Convention Center, Orlando, Florida between May 17-22, 2008. The Annual Meeting of AUA is the world's largest meeting of urologic professionals, genitourinary pathologists and basic science urologic researchers.

The CPDR team was led by COL (ret) David McLeod, MD, CPDR Director and Chief, Urologic Oncology at the Walter Reed Army Medical Center, Dr. Isabell Sesterhenn, Chief, Genitourinary Pathology at the Armed Forces Institute of Pathology (AFIP) and Dr. Shiv Srivastava, PhD, CPDR Co-Director and Professor at Uniformed Services University. The Center for Prostate Disease Research was represented by 7 moderated poster presentations at the AUA, during which the author is provided 2 minutes to explain the work to the interest group and the audience receives 2 minutes to question the presenter. All the CPDR presentations were in prostate cancer: Basic Science Research session.

The posters can be viewed in the following link: http://www.posters2view.com/aua08/.

The next AUA annual meeting is scheduled to be held between 25-30 April 2009 in Chicago, IL

Full Article

AACR 2008 Highlights

Friday, May 10, 2008

The Center for Prostate Disease Research, Rockville, MD was represented by some of their most prized talent and led by COL (ret) David McLeod, MD, CPDR Director and Chief, Urologic Oncology at the Walter Reed Army Medical Center, and Dr. Shiv Srivastava, PhD, CPDR Co-Director and Professor at Uniformed Services University.

Full Article

> CPDR MONTHLY SEMINAR

Wednesday, July 9, 2008
11:00 a.m. - 12:00 p.m.
CPDR, Rockville, MD

Wen Jin Wur, M.D., Ph.D.
Principal Investigator, Division of Monoclonal Antibodies
Center for Drug Evaluation and Research (CDER)
Food and Drug Administration (FDA)

Presenting: "The Roles of Cdc42 in Breast Cancer Progression "

Abstract

Cdc42, a Ras-like small GTPase, has been implicated in the regulation of cell growth. When aberrantly regulated, Cdc42 contributes to tumorigenesis and cancer metastasis. The EGF receptor (EGFR) is often overexpressed in human breast cancer. However, in most cases the mechanisms underlying the increased protein levels of EGF receptor are not known. An important mechanism for the termination of EGFR signaling is via Cbl-catalyzed EGFR ubiquitination and degradation.

Dr. Wur will focus on the discussion that up-regulated Cdc42 activity may impair c-Cbl mediated EGFR degradation and contributes to EGFR overexpression in human breast cancer cells. The second part of the talk will provide attendees with the evidence that activation of Cdc42, through an EGFR to Src-mediated signaling pathway, to enhance the ubiquitination and degradation of E-cadherin, which is an important adherens junction molecule and plays an essential role in maintaining epithelial polarity, in human breast cancer cells. the data supports a model that activation of Cdc42 contributes to mesenchyme-like phenotype by targeting of E-cadherin for lysosomal degradation.

Multi-center National Prostate Patient Database

Current Nomogram Predicting 5- and 10-year Overall Survival for Prostate Cancer (CaP) Patients

In 2006, CPDR launched its latest nomogram predicting 5- and 10-year overall survival for prostate cancer (CaP) patients who have undergone radical prostatectomy followed by a PSA recurrence. This tool demonstrates the importance of PSA doubling time in predicting time to death among CaP patients treated surgically.

These results were presented in an Abstract at the second annual American Society of Clinical Oncology (ASCO) Prostate Cancer Symposium, sponsored by ASCO, the Prostate Cancer Foundation, ASTRO, and the Society for Clinical Oncology (SUO).

Read Abstract

Go To Nomogram
(can only be viewed with IE 5.5 or higher)

> UPDATES

WRAMC UsToo!

Colonel Robert C. Dean, M.D., was our speaker for Wednesday, May 7, 2008 at 7 pm.

His topic was ““Life after Prostate Cancer: Effective Treatments for Erectile Dysfunction.”

This newsletter is published quarterly. Don't miss a single issue.

May 2008, Volume 17, Number 2